

Agila Specialties Investments Limited
Company Number: 08779682

These financial statements were prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

**Statement of Financial Position
at 30 November 2021**

	Note	2021 US\$	2020 US\$
Assets			
Non-current assets			
Investment in subsidiaries	1	5,163,546	5,163,546
Current assets			
Other receivables	2	19,300,753	19,300,753
Total Assets		<u>24,464,299</u>	<u>24,464,299</u>
Equity and Liabilities			
Capital and Reserves			
Share capital	3	2	2
Additional Paid in Capital	3	<u>19,300,751</u>	<u>19,300,751</u>
Total Equity		<u>19,300,753</u>	<u>19,300,753</u>
Current Liabilities			
Other payables	4	<u>5,163,546</u>	<u>5,163,546</u>
		5,163,546	5,163,546
Total Equity and Liabilities		<u>24,464,299</u>	<u>24,464,299</u>


The Notes on the following page are an integral part of these Financial Statements

For the financial year in question, the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies. No members have required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006. The Directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts. As permitted by Section 444 of the Companies Act 2006, the directors have not delivered to the Registrar a copy of the company's profit and loss account for the year ended 2021. These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.


Signature of Director

05/12/22
Date

Caroline Dixon
Director's Name in Print


Signature of Director

06/12/22
Date

Alan Weiner

THURSDAY



ABIG2UU1

A04

08/12/2022

#404

COMPANIES HOUSE

**Notes to the 30 November 2021 Agila Specialties Investments Limited Balance Sheet,
which has been prepared in accordance with IAS.IFRS**

Note 1

In December 2013, Agila Specialties Americas Limited (ASAL) deposited multiple US Dollar payments to Citi FX Desk to transfer BRL payments for ASIL's 24% investment in Agila Marketing e Distribuicao de Participacoes Ltda (Brazil). The value in US Dollars totalled \$2,857,321. In January 2014, ASAL deposited US\$2,306,226 on behalf of ASIL for future issue of Agila Marketing e Distribuicao de Participacoes shares. ASIL had no related transactions from 2015 through 2021.

Note 2

On 18 November 2013, Agila Specialties Americas Limited (ASAL) incorporated a new subsidiary called Agila Specialties Investments Ltd (ASIL) at a total cost of US\$19,300,753, which includes share capital of US\$2 and contribution of US\$19,300,751. An intercompany receivable for US\$ 19,300,753 from ASAL was recorded on the books of ASIL.

On 31 August 2019, ASAL transferred its share in ASIL to Mylan Pharmaceuticals PTE Limited (MPPL) prior to beginning procedures to wind up and liquidate the company.

Note 3

See Note 2 for the Share Capital and Additional Paid in Capital amounts.

Note 4

On 30 June 2016, the Board of Directors of ASAL, announced that ASAL would begin procedures to wind up and liquidate the company. In this process, ASIL settled its intercompany payable of US\$5,163,546 with ASAL by utilizing funds drawn on its account with Mylan Luxembourg 2 Sarl, Mylan's in-house bank; therefore, establishing another intercompany payable of US\$5,163,546.